Chronic Pain Treatment Global Market Report 2025

The chronic pain treatment market size has grown strongly in recent years. It will grow from $99.64 billion in 2024 to $109.05 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to the aging population, increasing prevalence of chronic diseases, heightened awareness of pain management, growth in prescription opioid use, and expansion of health insurance coverage.

The chronic pain treatment market size is expected to see strong growth in the next few years. It will grow to $155.0 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to a shift toward non-opioid alternatives, increased government funding for pain research, rising demand for personalized medicine, growing adoption of digital pain management tools, and expanding use of AI in pain diagnosis and treatment planning. Major trends during this period include advancements in neuromodulation therapies, integration of telemedicine into pain care, development of cannabinoid-based treatments, emphasis on multidisciplinary treatment approaches, and the rise of wearable pain monitoring devices.

The rising prevalence of arthritis pain is expected to significantly drive the growth of the chronic pain treatment market in the coming years. Arthritis pain, characterized by discomfort, aching, or soreness in the joints due to inflammation or degeneration, is increasingly common as the global population ages. The natural wear and tear on joints over time leads to a higher incidence of arthritis-related conditions, thereby increasing the demand for effective chronic pain management. Treatments targeting inflammation and nerve sensitivity help reduce pain, improve joint function, and enhance the quality of life for those suffering from persistent arthritis symptoms. For example, in March 2023, the Office for Health Improvement and Disparities, a UK government department, reported that 17.6% of individuals aged 16 and older had a long-term musculoskeletal condition, such as arthritis or chronic joint problems, in 2022 - an increase from 17% in 2021. Consequently, this growing prevalence is a key factor propelling the chronic pain treatment market forward.

Major companies operating in the chronic pain treatment market are focusing on developing innovative products like rechargeable spinal cord stimulators to improve patient convenience and enhance long-term pain management outcomes. A rechargeable spinal cord stimulator is an implantable medical device placed near the spine that delivers electrical pulses to disrupt pain signals, with the added benefit of being externally rechargeable, eliminating the need for additional surgeries. This technology helps manage chronic pain by blocking pain pathways in the spinal cord, thus reducing pain perception in patients suffering from conditions such as failed back surgery syndrome and neuropathic pain. For example, in December 2022, Abbott Laboratories, a US-based medical device company, launched the Eterna spinal cord stimulation system. Compact and discreet - smaller than an Apple AirPods case - this device offers significant pain relief, has shown potential in reducing opioid dependence, and is designed for minimally invasive, long-term use, ultimately improving patients’ daily functioning and quality of life.

In May 2025, electroCore Inc., a US-based bioelectronic technology company, acquired NeuroMetrix Inc. for an undisclosed amount. Through this acquisition, electroCore aims to bolster its leadership in the non-invasive bioelectronic therapy market by integrating NeuroMetrix’s Quell platform, thereby expanding its product portfolio and accelerating growth in the chronic pain and wellness sectors - especially within the Veterans Affairs (VA) Hospital System. NeuroMetrix Inc., based in the US, specializes in developing non-invasive therapeutic devices targeting chronic pain conditions like fibromyalgia.

Major players in the chronic pain treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Mallinckrodt plc, and Nevro Corp.

North America was the largest region in the chronic pain treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic pain treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic pain treatment involves ongoing management of pain lasting longer than three months, often extending beyond normal healing time. It typically combines medications, physical therapy, psychological support, and lifestyle modifications to reduce pain severity, improve functional abilities, and enhance overall quality of life.

The primary product types in chronic pain treatment include drugs and devices. Drugs for chronic pain work by targeting inflammation, nerve signaling, or underlying causes to alleviate persistent pain and improve patient outcomes. These medications address a variety of conditions such as neuropathic pain, arthritis, chronic back pain, cancer-related pain, migraine, fibromyalgia, and more. They are distributed through multiple channels, including both direct and indirect methods, and are utilized by a diverse set of end users including hospitals, clinics, nursing homes, research institutions, and universities.

The chronic pain treatment market research report is one of a series of new reports that provides chronic pain treatment market statistics, including the chronic pain treatment industry global market size, regional shares, competitors with the chronic pain treatment market share, detailed chronic pain treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic pain treatment industry. These chronic pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic pain treatment market consists of revenues earned by entities by providing services such as pharmacological treatment, physical therapy, psychological counseling, interventional pain management, alternative therapies, pain management clinics, and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pain treatment market also includes sales of lyrica, cymbalta, oxycontin, neurontin, voltaren gel, quell, and precision spectra spinal cord stimulator. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.